Clinical study of ctDNA-based MRD detection and INTERCEPT program update

Opinion
Video

The panel examines recent studies from the INTERCEPT program investigating the utility of circulating tumor DNA (ctDNA) for minimal residual disease (MRD) detection in colorectal cancer (CRC).

  1. Please describe some recent studies exploring the utility of ctDNA in CRC
  2. Dr Dasari: INTERCEPT program: ctDNA testing for MRD in CRC
  3. Association of positive ctDNA-based MRD assays during surveillance and undiagnosed concomitant radiographic recurrences CRC (Dasari, et al. ASCO 2023. Abstract 3522.)
  4. Results from a prospective real-world clinical cohort (Maddalena, et al. ASCO GI 2024. Abstract 27.)
Recent Videos
Alessio Pigazzi, MD, PhD, FACS, FASCRS, discussed surgical and medical oncology developments in the colorectal cancer field.
A panel of 3 experts on CML
A panel of 3 experts on CML
The Onc Brothers feature one guest in this series.
The Onc Brothers feature one guest in this series.
The Onc Brothers feature one guest in this series.
Related Content
Improved overall survival was also noted when atezolizumab plus bevacizumab and FOLFOXIRI were used to treat patients with pMMR tumors.

Atezolizumab Combo Improves Survival in Metastatic CRC

Ariana Pelosci
August 22nd 2024
Article

Improved overall survival was also noted when atezolizumab plus bevacizumab and FOLFOXIRI were used to treat patients with pMMR tumors.

Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

Optimizing Metastatic CRC Outcomes Following Fruquintinib Approval

Jagoda Misniakiewicz, PharmD
June 10th 2024
Podcast

Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

Managing high-grade squamous intraepithelial lesions may reduce the risk of anal cancer based on data from the phase 3 ANCHOR trial.

New HIV Guidelines Recommend Screening to Mitigate Anal Cancer Risk

Roman Fabbricatore
August 12th 2024
Article

Managing high-grade squamous intraepithelial lesions may reduce the risk of anal cancer based on data from the phase 3 ANCHOR trial.

Surgical oncologists from Cleveland Clinic discuss the National Accreditation Program for Rectal Cancer and its aim to improve patient outcomes.

Ensuring Quality Rectal Cancer Surgery at NAPRC-Accredited Institutions

Steven Wexner, MD, PhD;Arielle Kanters, MD
May 27th 2024
Podcast

Surgical oncologists from Cleveland Clinic discuss the National Accreditation Program for Rectal Cancer and its aim to improve patient outcomes.

The recommendation was made following mid-stage, end-of-phase 2 data for the botensilimab/balstilimab combination, which yielded lower responses in patients.

FDA Discourages Accelerated Approval of Botensilimab/Balstilimab Combo in R/R MSS CRC

Roman Fabbricatore
July 19th 2024
Article

The recommendation was made following mid-stage, end-of-phase 2 data for the botensilimab/balstilimab combination, which yielded lower responses in patients.

Expert Commentary on the Product Profile of Fruquintinib in Metastatic CRC

Expert Commentary on the Product Profile of Fruquintinib in Metastatic CRC

Jagoda Misniakiewicz, PharmD
July 11th 2024
Article

Jagoda Misniakiewicz, PharmD, discussed implementing fruquintinib into clinical practice and how it's mechanism of action compares with others in the space.